HC Wainwright reissued their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY - Free Report) in a research note issued to investors on Friday,Benzinga reports. They currently have a $7.50 price target on the stock.
Unicycive Therapeutics Price Performance
Shares of NASDAQ:UNCY traded down $0.00 during mid-day trading on Friday, reaching $0.59. 125,530 shares of the company traded hands, compared to its average volume of 1,444,508. The company's 50 day moving average price is $0.57 and its 200-day moving average price is $0.58. The firm has a market cap of $70.89 million, a PE ratio of -0.61 and a beta of 2.15. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.29.
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, research analysts predict that Unicycive Therapeutics will post -0.23 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Unicycive Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the stock. Nantahala Capital Management LLC increased its holdings in Unicycive Therapeutics by 268.5% in the 4th quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company's stock valued at $8,253,000 after acquiring an additional 7,571,636 shares during the last quarter. Octagon Capital Advisors LP grew its holdings in Unicycive Therapeutics by 16.8% during the 4th quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company's stock valued at $7,942,000 after buying an additional 1,441,000 shares in the last quarter. Vivo Capital LLC raised its holdings in shares of Unicycive Therapeutics by 123.0% during the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock worth $7,918,000 after acquiring an additional 5,500,000 shares in the last quarter. Acuta Capital Partners LLC grew its holdings in shares of Unicycive Therapeutics by 16.4% in the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock valued at $1,829,000 after purchasing an additional 323,801 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Unicycive Therapeutics by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after purchasing an additional 122,089 shares during the last quarter. Institutional investors own 40.42% of the company's stock.
Unicycive Therapeutics Company Profile
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Stories
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
